Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ibrutinib

FDA-approved product (capsule, oral), marketed as Ibrutinib, Imbruvica.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ibrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Macroglobulinemia
  • Mantle cell lymphoma
  • Neoplasm
  • Waldenstrom macroglobulinemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ibrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ibrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Mosunetuzumab for CLL MRD Clearance

    NCT07052695 · start 2025-11-24

    Registered record
    Registry ID
    NCT07052695
    Conditions
    Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
    Interventions
    Mosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-11-24
    Completion
    2032-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
    InterventionMosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

    NCT07169565 · start 2025-09-01

    Registered record
    Registry ID
    NCT07169565
    Conditions
    Waldenström Macroglobulinemia (WM)
    Interventions
    Ibrutinib; Bendamustine; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2028-09-01
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenström Macroglobulinemia (WM)
    InterventionIbrutinib; Bendamustine; Rituximab
    PhasePhase 1
    Registry statusNot yet recruiting

  • SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

    NCT07021495 · start 2025-07-29

    Registered record
    Registry ID
    NCT07021495
    Conditions
    Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD); CTCL/ Mycosis Fungoides
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-29
    Completion
    2029-12-31
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD) +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

    NCT06357676 · start 2025-05-29

    Registered record
    Registry ID
    NCT06357676
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Echocardiography; FDG-Positron Emission Tomography; Glofitamab; Ibrutinib; Magnetic Resonance Imaging; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-05-29
    Completion
    2029-11-01
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionBiospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Echocardiography +5 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

    NCT06561243 · start 2024-07-25

    Registered record
    Registry ID
    NCT06561243
    Conditions
    Chronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases
    Interventions
    BTK inhibitor (Ibrutinib or Acalabrutinib)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-07-25
    Completion
    2024-10-30
    Enrolment
    15,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic B-cell Malignancies; BTK Inhibitors; Cardiovascular Diseases
    InterventionBTK inhibitor (Ibrutinib or Acalabrutinib)
    PhaseNot recorded
    Registry statusUnknown

  • Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

    NCT05495828 · start 2023-11-10

    Registered record
    Registry ID
    NCT05495828
    Conditions
    B-cell Lymphoma
    Interventions
    Orelabrutinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-11-10
    Completion
    2025-03-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Lymphoma
    InterventionOrelabrutinib
    PhaseNot recorded
    Registry statusUnknown

  • Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

    NCT05744037 · start 2023-01-01

    Registered record
    Registry ID
    NCT05744037
    Conditions
    B-cell Non Hodgkin Lymphoma
    Interventions
    regimen with BTK inhibitor +Anti-CD19 CAR T cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-01-01
    Completion
    2025-01-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Non Hodgkin Lymphoma
    Interventionregimen with BTK inhibitor +Anti-CD19 CAR T cells
    PhasePhase 2
    Registry statusUnknown

  • Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

    NCT04781855 · start 2022-07-14

    Registered record
    Registry ID
    NCT04781855
    Conditions
    Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Richter Syndrome
    Interventions
    Ibrutinib; Ipilimumab; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2022-07-14
    Completion
    2025-02-21
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic and Lymphoid Cell Neoplasm; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia +2 more
    InterventionIbrutinib; Ipilimumab; Nivolumab
    PhasePhase 1
    Registry statusWithdrawn

  • Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

    NCT04802590 · start 2022-01-24

    Registered record
    Registry ID
    NCT04802590
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Ibrutinib 560 mg; Venetoclax 10 MG Oral Tablet [Venclexta]; Venetoclax 50 MG Oral Tablet [Venclexta]; Venetoclax 100 MG Oral Tablet [Venclexta]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-01-24
    Completion
    2030-03-02
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionIbrutinib 560 mg; Venetoclax 10 MG Oral Tablet [Venclexta]; Venetoclax 50 MG Oral Tablet [Venclexta]; Venetoclax 100 MG Oral Tablet [Venclexta]
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    NCT04840602 · start 2022-01-05

    Registered record
    Registry ID
    NCT04840602
    Conditions
    Lymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Ibrutinib; Positron Emission Tomography; Rituximab; Venetoclax; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-01-05
    Completion
    2028-03-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +5 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib

    NCT05491044 · start 2022-01-01

    Registered record
    Registry ID
    NCT05491044
    Conditions
    CLL/SLL
    Interventions
    orelabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-01-01
    Completion
    2024-08-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCLL/SLL
    Interventionorelabrutinib
    PhasePhase 2
    Registry statusUnknown

  • MEOI and HRQoL in CLL Patients Treated With BTKis

    NCT04938141 · start 2021-10-07

    Registered record
    Registry ID
    NCT04938141
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-10-07
    Completion
    2024-09-26
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

    NCT04994626 · start 2021-10-01

    Registered record
    Registry ID
    NCT04994626
    Conditions
    DLBCL; MYD88 Gene Mutation; CD79A Gene Mutation; CD79B Gene Mutation; Relapse; Refractory Lymphoma
    Interventions
    Ibrutinib Combined With Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-10-01
    Completion
    2025-07-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDLBCL; MYD88 Gene Mutation; CD79A Gene Mutation; CD79B Gene Mutation +2 more
    InterventionIbrutinib Combined With Rituximab
    PhasePhase 2
    Registry statusUnknown

  • ECP Combination Study

    NCT05052385 · start 2021-04-13

    Registered record
    Registry ID
    NCT05052385
    Conditions
    Steroid Refractory GVHD
    Interventions
    Ruxolitinib; Extracorporeal photopheresis; Ibrutinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-04-13
    Completion
    2022-06-15
    Enrolment
    319

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSteroid Refractory GVHD
    InterventionRuxolitinib; Extracorporeal photopheresis; Ibrutinib
    PhaseNot recorded
    Registry statusCompleted

  • Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

    NCT04607772 · start 2020-11-18

    Registered record
    Registry ID
    NCT04607772
    Conditions
    Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Interventions
    Selinexor; Rituximab; Bendamustine; Polatuzumab Vedotin; Ibrutinib; Lenalidomide; Tafasitamab; Venetoclax; Gemcitabine; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2020-11-18
    Completion
    2025-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Diffuse Large B-Cell Lymphoma
    InterventionSelinexor; Rituximab; Bendamustine; Polatuzumab Vedotin +6 more
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn